Pharmacological interventions other than botulinum toxin for spasticity after stroke

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Lindsay, Cameron ^a   Pandyan, Anand D ^b  

^a CITY HOSPITAL   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BACLOFEN; BOTULINUM TOXIN; DANTROLENE; PHENOL; TIZANIDINE; TOLPERISONE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CONTRACTURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EARLY INTERVENTION; HUMAN; PAIN; PRIORITY JOURNAL; SPASTICITY; STUDY DESIGN; SYSTEMATIC REVIEW; THERAPY DELAY;

EID: 85048471363     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010362     Document Type: Article

References (37)

1. Ada L, O'Dwyer N, O'Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disability & Rehabilitation 2006;28(13):891-7.
2. Adamson J, Beswick A, Ebrahim S. Is stroke the most common cause of disability?. Journal of Stroke and Cerebrovascular Diseases 2004; Vol. 13, issue 4:171-7.
3. Barnes MP. Management of spasticity. Age and Ageing 1998;27(2):239-45.
4. Bogey RA, Geis CC, Bryant PR, Moroz A, O'Neill BJ. Stroke and neurodegenerative disorders. 3. Stroke: rehabilitation management. Archives of Physical Medicine and Rehabilitation 2004;85(3):S15-20, S34-40.
5. Burke D. Spasticity as an adaptation to pyramidal tract injury. Advances in Neurology 1988;47:401.
6. Davidoff RA. Antispasticity drugs: mechanisms of action. Annals of Neurology 1985;17(2):107-16.
7. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
8. Esquenazi A. The human and economic burden of poststroke spasticity and muscle overactivity. Journal of Clinical Outcomes Management 2011;18(1):34-44.
9. Gallichio JE. Pharmacologic management of spasticity following stroke. Physical Therapy 2004;84(10):973-81.
10. Gormley ME, O'Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spasticity. Muscle and Nerve Supplement 1997;20(S6):S14-S20.
11. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle & Nerve Supplement. Wiley, 1997; Vol. 20, issue S6:S92-120.
12. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
13. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
14. Howe JR, Sutor B, Zieglgänsberger W. Baclofen reduces post-synaptic potentials of rat cortical neurones by an action other than its hyperpolarizing action. Journal of Physiology 1987;384:539-69.
15. Kocabas H, Salli A, Demir AH, Ozerbil OM. Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. European Journal of Physical and Rehabilitation Medicine 2010;46(1):5-10.
16. Krach LE. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. Journal of Child Neurology 2001;16(1):31-6.
17. Lyons BE, Moore P, Bhakta BB, Bamford JM, Cardwell C, Logan ID. Botulinum toxin for adult spasticity after stroke or non-progressive brain lesion. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002926.pub2]
18. Malhotra S, Cousins E, Ward A, Day C, Jones P, Roffe C, et al.An investigation into the agreement between clinical, biomechanical and neurophysiological measures of spasticity. Clinical Rehabilitation 2008;22(12):1105-15.
19. Malhotra S, Pandyan AD, Day CR, Jones PW, Hermens H. Spasticity, an impairment that is poorly defined and poorly measured. Clinical Rehabilitation 2009;23(7):651-8.
20. Mirbagheri MM, Lilaonitkul T, Rymer WZ. Prediction of natural history of neuromuscular properties after stroke using Fugl-Meyer scores at 1 month. Neurorehabilitation and Neural Repair 2011;25(5):458-68.
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 2009;151(4):264.
22. Monaghan K, Horgan F, Blake C, Cornall C, Hickey PPM, Lyons BE, et al.Physical treatment interventions for managing spasticity after stroke. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD009188]
23. Mukherjee A, Chakravarty A. Spasticity mechanisms - for the clinician. Frontiers In Neurology 2010;1:149.
24. Palmeri A, Wiesendanger M. Concomitant depression of locus coeruleus neurons and of flexor reflexes by an alpha 2-adrenergic agonist in rats: a possible mechanism for an alpha 2-mediated muscle relaxation. Neuroscience 1990;34(1):177-87.
25. Pandyan AD, Gregoric M, Barnes MP, Wood D, van Wijck F, Burridge J, et al.Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disability & Rehabilitation 2005;27(1):2-6.
26. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
27. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity In Adults: Management Using Botulinum Toxin. National Guidelines. London: RCP, 2009.
28. Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, et al.The lifetime risk of stroke. Stroke 2006;37(2):345-50.
29. Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Safety 2006;29(1):31-48.
30. Sheean G. Botulinum toxin should be first-line treatment for poststroke spasticity. Journal of Neurology, Neurosurgery & Psychiatry 2009;80(4):359.
31. Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. European Journal of Neurology 2010;17:74-93.
32. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A, the BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. Journal of Neurology, Neurosurgery & Psychiatry 2009;80(4):380-5.
33. Sorinola IO, White CM, Rushton DN, Newham DJ. Electromyographic response to manual passive stretch of the hemiplegic wrist: accuracy, reliability, and correlation with clinical spasticity assessment and function. Neurorehabilitation and Neural Repair 2009;23(3):287-94.
34. van Tulder MW, Assendelft WJJ, Koes BW, Bouter LM, the Editorial Board of the Cochrane Collaboration Back Review Group. Method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine 1997;22(20):2323-30.
35. Vora A. Tolperisone. Journal of the Association of Physicians of India 2010;58:127-8.
36. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clinical Rehabilitation 2002;16(5):515-22.
37. Willerslev-Olsen M, Lundbye-Jensen J, Petersen T, Nielsen J. The effect of baclofen and diazepam on motor skill acquisition in healthy subjects. Experimental Brain Research 2011; Vol. 213, issue 4:465-74.